Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02859519 · ClinicalTrials.gov registry record · Phase 3
A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
A Phase 3 study of Distal, Subungual Onychomycosis, sponsored by Moberg Pharma AB.
- Completed
- Registry status
- Phase 3
- Development phase
- 365
- Enrollment target
- 10
- Study locations
NCT02859519 is a Phase 3 study of Distal, Subungual Onychomycosis that has completed, run by Moberg Pharma AB. The registered enrollment target is 365 participants. The trial reports 10 study locations across 10 states.
The verdict
NCT02859519, a Phase 3 study of Distal, Subungual Onychomycosis, has completed, sponsored by Moberg Pharma AB.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 365 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of topical MOB015B in patients with mild to moderate distal subungual onychomycosis (DSO). The secondary objective is to evaluate the safety of topical MOB015B in patients with mild to moderate DSO.
Conditions Studied
Interventions
- DRUG MOB015B
- DRUG MOB015B Vehicle
Study Locations (10)
California
- - Multiple Locations
Florida
- - Multiple Locations
Idaho
- - Multiple Locations
Illinois
- - Rolling Meadows
Minnesota
- - Fridley
New Jersey
- - Multiple Locations
Oregon
- - Multiple Locations
Texas
- - Multiple Locations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-11-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02859519
The ClinicalTrials.gov registry entry for NCT02859519 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Moberg Pharma AB, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Distal, Subungual Onychomycosis appearing as the primary indexed condition, and to 2 interventions - of which MOB015B is the first listed.
NCT02859519 reports 10 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Idaho.
Frequently Asked Questions
What is clinical trial NCT02859519 about?
NCT02859519 is a clinical study titled "A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)". The primary objective of this study is to evaluate the efficacy of topical MOB015B in patients with mild to moderate distal subungual onychomycosis (DSO). The secondary objective is to evaluate the safety of topical MOB015B in patients with mild to moderate DSO.
What is the current status of trial NCT02859519?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 365 participants. The study started on 2016-10. Estimated completion is 2019-11-13.
What conditions does trial NCT02859519 study?
This clinical trial studies the following conditions: Distal, Subungual Onychomycosis.
What interventions are being tested in trial NCT02859519?
The interventions under investigation include: MOB015B (DRUG), MOB015B Vehicle (DRUG).
Who is sponsoring clinical trial NCT02859519?
This trial is sponsored by Moberg Pharma AB, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02859519 being conducted?
This trial has 10 study locations across California, Florida, Idaho, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Distal, Subungual Onychomycosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.